Ibio Inc (NYSEAMERICAN: IBIO) terms its preclinical studies of IBIO-202 inspiring. The IBIO-202 happens to be its subunit vaccine candidate, and its development is geared towards dealing with the nucleocapsid protein (“N protein”) of SARS-CoV-2. The company reveals details about the study, outlining that it demonstrated an antigen-specific, strong, memory T-cell response.
Evaluating the studies
Analysts believe there is a lot to decipher from the data on commercially available COVID-19 vaccines. They happen to be vaccines meant to target the spike protein. Analysts say that the details a lot about the effectiveness of the neutralizing titers. However, they express fears that the neutralizing titers have a significant likelihood of waning over time.
Analysts applaud the robustness of T-cell cellular and priming immunity achieved by S protein-directed vaccines. However, they express fears that they might not be sufficient when it comes to developing a durable immune response. The analysts had been speaking in the context of emerging variant strains of the virus.
There happens to be a rather sharp contrast when scientists check it against the N protein gene, which happens to be more stable and conserved than the spike. Moreover, the N protein gene is characterized by a 90% amino acid homology, and the mutations over time happen to be relatively minimal.
Focusing on the N protein
One of the most exciting attributes of the N protein is its effect on inducing SARS-specific T-cell proliferation. The T-cell priming was possible via both the intranasal and intramuscular administration. Thus, it was possible to explore the various means of administration and the associated merits.
The studies showing the recovery of SARS-CoV-2 infection patients revealed the essence of the combination of N-directed and S-directed immunity.Scientists evaluated convalescent sera.
The company’s CSO Martin Brenner states, “Accordingly, we believe the N protein strategy of IBIO-202 may be complementary with existing S-directed vaccines, conferring additional protective effects that more closely mimic the natural immune responses of patients that have cleared the virus.”